Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial

Impact · against what's priced in

ELTX shares should react positively to Phase 2 data showing that an off-the-shelf therapy can trigger personalized immune responses (antigen spreading). This clinical de-risking suggests higher potential efficacy and lower tumor evasion rates than a standard off-the-shelf approach would imply.

ELTX+0.60

No priced-in read yet